glycyrrhizic acid has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azhdari, S; Karimzadeh, MR; Omidi, F; Reiisi, S; Shahbazi, S | 1 |
| Jang, ER; Kim, W; Kim, YJ; Lee, CS; Myung, SC; Yang, JC | 1 |
2 other study(ies) available for glycyrrhizic acid and Cancer of Ovary
| Article | Year |
|---|---|
Glycyrrhizic acid enhances the anticancer activity of cisplatin in the human ovarian cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Glycyrrhizic Acid; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Ovarian Neoplasms; Superoxide Dismutase | 2023 |
18β-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Fragmentation; Drug Synergism; Enzyme Activation; Female; Glycyrrhetinic Acid; Glycyrrhizic Acid; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mitochondria; Ovarian Neoplasms; Prodrugs; Tumor Suppressor Protein p53 | 2010 |